Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 24 for “"FAERS"”.
-
Analysis of Adverse Events Associated with SGLT2 Inhibitors and Molecular Mechanisms Using FAERS Database and Transcriptome Data
… Administration Adverse Event Reporting System (FAERS) database to assess adverse events, including myocardial infarction, cardiac failure, tachycardia, acute kidney injury (AKI), renal failure, urinary tract infections, and fungal infections. This analysis was complemented by transcriptomic data …
-
COMPARISON OF POST-MARKETING SURVEILLANCE APPROACHES REGARDING INFECTIONS RELATED TO TUMOR NECROSIS FACTOR (TNF) INHIBITORS
… contrast the FDA Adverse Event Reporting System (FAERS) data and findings from observational studies in post-marketing surveillance through examining TNF inhibitors (etanercept, adalimumab, infliximab, certolizumab and golimumab) related infections, and secondarily, to examine the applicability of …
-
Analysis of the Safety Profile of Cannabis-Derived Products Using the FDA Adverse Event Reporting System Databases
… Administration Adverse Event Reporting System (FAERS) is a valuable tool for the rapid detection of unexpected emerging safety signals using real-world data. We conducted a descriptive analysis and a disproportionality analysis of CDP-related spontaneous adverse event reports (AERs) queried from …
-
Identifying Unexpected Inflammation Resulting from Drug-Drug Interactions
… from FDA’s Adverse Event Reporting System (FAERS), when combined (in groups of two or more), elicit an inflammatory response and if drug pairs were identified as causing inflammation what were the symptoms? Methods: In this study secondary data was analyzed from the publicly available FAERS …
-
Τεχνολογίες δεδομένων μεγάλης κλίμακας και ανίχνευση ανεπιθύμητων ενεργειών φαρμάκων - φαρμακοεπαγρύπνηση
… terms we collected and analysed reports from FAERS, for the same period. We also retrieved user posts from Twitter and using an advanced Naïve-Bayes algorithm we detected references of adverse events. Results were analysed using statistics and compared to those of the official adverse event …
-
Translational high-dimesional drug interaction discovery and validation using health record databases and pharmacokinetics models
… risk of myopathy were identified in the FAERS and EMR databases by a mixture drug-count response model (MDCM) model. Twenty-eight 3-way and 43 4-way DDI’s increased ratio of area under plasma concentration–time curve (AUCR) >2-fold and had significant myopathy risk in both databases. The …
-
An Economic and Regulatory Analysis of Gene Therapy Products Authorized by the US Food and Drug Administration and the European Medicines Agency
… to the FDA Adverse Event Reporting System (FAERS), and assessed the cost-effectiveness analysis of three gene therapies axicabtagene ciloleucel(axi-cel), lisocabtagene maraleucel (liso-cel), and tisagenlecleucel (tisa-cel). Research Design: For aim 1; data was collected using regulatory …
-
Incidence of adverse drug events in COVID-19 patients on anticoagulants: a pharmacovigilance study
… from the FDA’s Adverse Event Reporting System (FAERS) Public Database. Chi-square test of association was performed to determine associations of race, sex and hospitalization rate with the adverse outcome variables. Proportional Reporting Ratios (PRR) and lower 95% confidence intervals (Lower …
-
Development and Validation of Predictive Risk and Multiple Criteria Decision Analysis Models to Evaluate Cardiovascular Outcomes Among Cancer Patients
… (MEPS) and FDA Adverse Events Reporting System (FAERS) 2005-2015 files along with literature evidence for our study. We used MEPS database to train our predictive models using ML algorithms such as random forest (RF), gradient boosting and deep learning and compared these to standard regression …
-
Adverse drug reactions associated with antibiotics : an analysis of the FDA Adverse Event Reporting System
… limited. The FDA Adverse Event Reporting System (FAERS) provides real-world data on ADRs of antibiotics. Using FAERS, this study 1) discovered new ADR associations for FDA-approved antibiotics, 2) identified an antibiotic-ADR association that was worse for patients on two drugs than on either drug …
-
From Cardiovascular Safety Assessment to Peptide Hemolytic Activity Prediction: Integrative Computational Analyses for Drug Evaluation and Discovery
… from the FDA Adverse Event Reporting System (FAERS), electronic health records (EHRs) from TriNetX, and transcriptomic analyses were combined to evaluate anesthetic-associated cardiac rhythm adverse drug events. Among propofol, ketamine, dexmedetomidine, and midazolam, dexmedetomidine showed …
-
Using Machine Learning On Diverse Datasets To Predict Drug-Induced Liver Injury
… (TOX21), and FDA reporting of adverse events (FAERS). Four types of DILI classes were targeted, including two clinically relevant scores and two control classifications, designed by the CAMDA organizers. The L1000 gene expression data had variable drug coverage across cell lines with only 247 …
-
Optimization of Signal-Detection Methods in Novel Databases: a Focus on Direct-Acting Antivirals
… (FDA) Adverse Event Reporting System (FAERS) is a database containing ADE reports that were submitted to the FDA. The reports need to be investigated, and when working with large databases, signal detection algorithms (SDA) are used to decide which reports are significant. Signal …
-
THE ROLE OF HYPOGLYCEMIC AGENTS IN AMELIORATING COGNITIVE FUNCTIONS AND PSYCHIATRIC SYMPTOMS: FROM THE PSYCHIATRIC PATIENT TO EVIDENCE-BASED AND PHARMACOEPIDEMIOLOGIC APPROACHES FOR SUPPORTING THE CLINICAL PRACTICE
… PPR(p)= 1.07 (0.00), EBGM95=0.96 ERAM95=0.89 in FAERS and ROR95=1.48 PPR(p)= 1.34 (0.00) EBGM95=1.22 and ERAM95=0.86 in VigiBase]. GLP-1a and DPP-4 inhibitors (DPP-4i) resulted in better outcomes with a preference for GLP-1a for reducing the risk of major cognitive impairment (dementia) in old …
-
A pharmacoepidemiological analysis of off-label use of marketed drugs and serious adverse drug reactions
… Administration Adverse Event Reporting System (FAERS) is presented. Another fifteen cases were identified in the FAERS between 2007 and 2010. Careful monitoring of clinical and laboratory signs of hepatic injury is warranted in patients receiving TZM. In publication 3 characteristics of cases …
-
Analyzing Adverse Events from Publicly Available Web Sources
… via the FDA Adverse Event Reporting System (FAERS) and privatized reporting systems that house the data from clinical trials. Our focus will be on building a pipeline that demonstrates an open source solution for building a drug’s safety profile from data collection through signal detection. …
-
Association Between Use of Remdesivir and Bradycardia
… from the FDA Adverse Event Reporting System (FAERS) database. Patients receiving remdesivir were compared to those receiving Paxlovid, Regen-Cov, and Dexamethasone for COVID-19 treatment to see which group of patients were at a higher risk for bradycardia. This study also sought to determine …
-
Systemic Quinolones and Risk of Adverse Reactions: Integrating Evidence from Clinical and Epidemiological Evidence Streams
… than 500 hospitals between 2000 and 2016. The FAERS analysis revealed a positive ALF signal with ciprofloxacin and a marginal signal for RD with moxifloxacin. Examination of the evidence from clinical trials revealed only two cases of ALF, one associated with gemifloxacin and one with …
-
Contributions to Methods for Adverse Event Identification
… such as the FDA Adverse Event Reporting System (FAERS) database, provide critical first alerts for emerging medical product safety concerns.In this thesis, we first conduct a comprehensive review of the existing adverse event identification methods, with special emphasis on the postmarketing …
-
Αγωνιστές των υποδοχέων του πεπτιδίου-1 όμοιου με τη γλυκαγόνη (GLP-1 RAs) και αναστολείς του συμμεταφορέα νατρίου-γλυκόζης-2 (SGLT-2): Αντιδιαβητική θεραπεία και ο κίνδυνος νεοπλασμάτων του θυρεοειδούς: Συστηματική ανασκόπηση και μετα-ανάλυση.
… η εξαίρεση των μελετών φαρμακοεπαγρύπνησης (FAERS) κατά την ανάλυση ευαισθησίας οδήγησε σε στατιστική σταθεροποίηση και εξάλειψη των μεροληψιών με σταθερό OR 0.81 (95% CI: 0.61–1.09, I2 = 77.9%). Η ανάλυση υποομάδων με βάση την οδό χορήγησης επιβεβαίωσε ότι οι σύγχρονες από του στόματος …
Page 1 of 2